Furagin (Tablets, Capsules) Instructions for Use

Instructions
Dosage forms

ATC Code

J01XE (Nitrofuran derivatives)

Active Substance

Furazidin (BP British Pharmacopoeia)

Clinical-Pharmacological Group

Antibacterial drug, a derivative of nitrofuran. Urinary antiseptic

Pharmacotherapeutic Group

Systemic antibacterial agents; other antibacterial agents; nitrofuran derivatives

Pharmacological Action

An antimicrobial agent with a broad spectrum of activity, belonging to the nitrofuran group. The mechanism of action is associated with the inhibition of nucleic acid synthesis.

Under the influence of nitrofurans, the activity of the respiratory chain and the tricarboxylic acid cycle (Krebs cycle) is suppressed, as well as other biochemical processes of microorganisms are inhibited, which leads to the destruction of their cell wall or cytoplasmic membrane.

Active against gram-positive cocci Staphylococcus spp., Streptococcus spp.; gram-negative rods Escherichia coli, Salmonella spp., Shigella spp., Klebsiella spp.

Resistant to furazidin are Pseudomonas aeruginosa, Enterococcus spp., Acinetobacter spp., most strains of Proteus spp., Serratia spp.

Depending on the concentration, it has a bactericidal or bacteriostatic effect. For most bacteria, the bacteriostatic concentration ranges from 10 to 20 µg/ml. The bactericidal concentration is approximately 2 times higher.

Pharmacokinetics

After oral administration, Furazidin is absorbed from the small intestine by passive diffusion. The absorption of nitrofurans from the distal segment of the small intestine exceeds absorption from the proximal and medial segments by 2 and 4 times, respectively (should be taken into account during simultaneous treatment of urogenital infections and gastrointestinal diseases, in particular chronic enteritis). Nitrofurans are poorly absorbed from the large intestine.

C_max in blood plasma persists for 3 to 7 or 8 hours; Furazidin is detected in urine after 3-4 hours.

In the body, Furazidin is distributed evenly. The high content of the drug in the lymph is clinically important (it delays the spread of infection through the lymphatic pathways). Its concentration in bile is several times higher than in serum, and in cerebrospinal fluid it is several times lower than in serum. The furazidin content in saliva is 30% of its concentration in serum. The concentration of furazidin in the blood and tissues is relatively low, which is associated with its rapid excretion, while the concentration in urine is significantly higher than in blood.

It is metabolized to a small extent (<10%).

It is excreted by the kidneys through glomerular filtration and tubular secretion (85%), partially undergoes reabsorption in the tubules. At low concentrations of furazidin in urine, the processes of filtration and secretion predominate; at high concentrations, secretion decreases and reabsorption increases. Furazidin, being a weak acid, does not dissociate in acidic urine, undergoes intensive reabsorption, which can enhance the development of systemic side effects. With an alkaline urine reaction, the excretion of furazidin is enhanced.

With a decrease in the excretory function of the kidneys, the intensity of metabolism increases.

Indications

For oral administration: urogenital infections (acute cystitis, urethritis, pyelonephritis); gynecological infections; skin and soft tissue infections; severe infected burns; for prophylactic purposes in urological operations (including cystoscopy, catheterization).

For external and topical use: infectious and inflammatory diseases of the oral cavity and pharynx, infected wounds.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
J02	Acute pharyngitis
J03	Acute tonsillitis
J31.2	Chronic pharyngitis
J35.0	Chronic tonsillitis
K05	Gingivitis and periodontal diseases
K12	Stomatitis and related lesions
L01	Impetigo
L02	Cutaneous abscess, furuncle and carbuncle
L03	Cellulitis
L08.0	Pyoderma
L08.8	Other specified local infections of skin and subcutaneous tissue
N10	Acute tubulointerstitial nephritis (acute pyelonephritis)
N11	Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30	Cystitis
N34	Urethritis and urethral syndrome
N41	Inflammatory diseases of prostate
N70	Salpingitis and oophoritis
N71	Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72	Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N73.0	Acute parametritis and pelvic cellulitis
T79.3	Posttraumatic wound infection, not elsewhere classified
Z29.2	Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes)

ICD-11 code	Indication
1B70.1	Streptococcal cellulitis of the skin
1B70.2	Staphylococcal cellulitis of the skin
1B70.Z	Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0	Bullous impetigo
1B72.1	Nonbullous impetigo
1B72.Z	Impetigo, unspecified
1B75.0	Furuncle
1B75.1	Carbuncle
1B75.2	Furunculosis
1B75.3	Pyogenic skin abscess
1B7Y	Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1C44	Non-pyogenic bacterial infections of skin
CA02.Z	Acute pharyngitis, unspecified
CA03.Z	Acute tonsillitis, unspecified
CA09.2	Chronic pharyngitis
CA0F.Y	Other specified chronic diseases of the palatine tonsils and adenoids
DA01.Z	Diseases of the oral mucosa, unspecified
DA0B.Z	Gingival diseases, unspecified
DA0C.Z	Periodontal diseases, unspecified
DA0Z	Diseases or disorders of the orofacial complex, unspecified
EA50.3	Staphylococcal scarlet fever
EB21	Pyoderma gangrenosum
GA01.Z	Inflammatory diseases of uterus, except cervix, unspecified
GA05.0	Acute inflammatory disease of female pelvic organs
GA07.Z	Salpingitis and oophoritis, unspecified
GA91.Z	Inflammatory and other diseases of prostate, unspecified
GB50	Acute tubulo-interstitial nephritis
GB51	Acute pyelonephritis
GB55.Z	Chronic tubulo-interstitial nephritis, unspecified
GB5Z	Renal tubulo-interstitial diseases, unspecified
GC00.Z	Cystitis, unspecified
GC02.Z	Urethritis and urethral syndrome, unspecified
NF0A.3	Posttraumatic wound infection, not elsewhere classified
QC05.Y	Other specified prophylactic measures
GA0Z	Inflammatory diseases of female genital tract, unspecified
XA5WW1	Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets, Capsules

For oral administration, a single dose is 25-100 mg, depending on age and indications.

The frequency of application during the day depends on the indications for use.

The course of treatment is 7-10 days. If it is necessary to repeat the course of treatment, a break of 10-15 days should be taken.

Externally 2-3 times/day for washing wounds or moistening dressing material.

Topically 2-3 times/day in the form of gargles for the oral cavity and pharynx.

Adverse Reactions

From the blood and lymphatic system agranulocytosis, thrombocytopenia, aplastic anemia.

From the immune system skin itching, papular rash, angioedema, urticaria, exfoliative dermatitis, multiforme erythema.

From the nervous system dizziness, headache, drowsiness, peripheral neuropathy.

From the organ of vision visual impairment.

From the cardiovascular system intracranial hypertension.

From the respiratory system acute or chronic pulmonary reaction, which manifests as acute dyspnea, fever, chest pain, cough with or without sputum, eosinophilia (reversible after drug discontinuation). The appearance of skin rash, itching, urticaria, angioedema and myalgia has also been reported. A chronic pulmonary reaction may occur over a long period after cessation of treatment and is characterized by a gradual increase in dyspnea, increased respiratory rate, intermittent fever, eosinophilia, progressive cough and interstitial pneumonitis and/or pulmonary fibrosis.

From the digestive system nausea, vomiting, decreased appetite, diarrhea, pancreatitis.

From the liver and biliary tract cholestatic jaundice, hepatitis.

From the musculoskeletal system arthralgia.

General disorders frequency unknown – fever, weakness, reversible alopecia, dark yellow or brown discoloration of urine.

Contraindications

Hypersensitivity to furazidin and nitrofuran derivatives; severe chronic renal failure (GFR < 30 ml/min); polyneuropathy (including diabetic); porphyria; pregnancy, breastfeeding period; for oral administration in dosage forms containing 50 mg or 100 mg of furazidin – children and adolescents under 18 years of age; for oral administration at a dose of 25 mg – children under 3 years of age; for external and topical use – children under 4 years of age.

With caution

Glucose-6-phosphate dehydrogenase deficiency, mild to moderate renal impairment, hepatic impairment, anemia, deficiency of B vitamins and folic acid, lung diseases (especially in patients over 65 years of age), diabetes mellitus.

Use in Pregnancy and Lactation

The use of the drug is contraindicated during pregnancy and lactation (breastfeeding).

Use in Renal Impairment

Contraindicated in severe chronic renal failure.

Pediatric Use

Contraindicated for oral administration in dosage forms containing 50 mg or 100 mg of furazidin – children and adolescents under 18 years of age; for oral administration at a dose of 25 mg – children under 3 years of age; for external and topical use – children under 4 years of age.

Geriatric Use

Use with caution in lung diseases, especially in patients over 65 years of age.

Special Precautions

To reduce the likelihood of side effects, Furazidin should be taken with plenty of fluids.

If side effects occur, use should be discontinued (toxic phenomena are more common in patients with reduced renal excretory function).

During treatment, the patient is advised to refrain from consuming alcohol, as side effects may be enhanced.

Do not take a double dose to compensate for a missed dose.

Use with caution in glucose-6-phosphate dehydrogenase deficiency.

Drug Interactions

When furazidin is combined with ristomycin, chloramphenicol, sulfonamides, the risk of hematopoiesis suppression increases (should not be used simultaneously).

It is not recommended to use drugs that can acidify urine (including ascorbic acid, calcium chloride) simultaneously with nitrofurans.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Furagin [Aliym, JSC (Russia)]
Tablets 50 mg: 10, 15, 20, 30, 45, 60, or 90 pcs.

Marketing Authorization Holder

Aliym, JSC (Russia)

Dosage Form

Furagin

Tablets 50 mg: 10, 15, 20, 30, 45, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Furazidin	50 mg

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.

Furagin [Ozon, LLC (Russia)]
Tablets 50 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 240, or 300 pcs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Furagin

Tablets 50 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 240, or 300 pcs.

Dosage Form, Packaging, and Composition

Tablets from yellow to yellow with an orange tint, flat-cylindrical in shape, with a bevel and a score line.

	1 tab.
Furazidin	50 mg

Excipients : lactose monohydrate (milk sugar) – 36 mg, potato starch – 7 mg, povidone K25 – 4 mg, croscarmellose sodium – 2 mg, magnesium stearate – 1 mg.

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard boxes.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (10) – cardboard packs.
30 pcs. – blister packs (1) – cardboard packs.
30 pcs. – blister packs (2) – cardboard packs.
30 pcs. – blister packs (3) – cardboard packs.
30 pcs. – blister packs (4) – cardboard packs.
30 pcs. – blister packs (5) – cardboard packs.
30 pcs. – blister packs (6) – cardboard packs.
30 pcs. – blister packs (8) – cardboard packs.
30 pcs. – blister packs (10) – cardboard packs.

Furagin [Onlinepharm, JSC (Latvia)]
Tablets 50 mg: 10, 20, 30, 40, 50, or 13500 pcs.

Marketing Authorization Holder

Onlinepharm, JSC (Latvia)

Dosage Form

Furagin

Tablets 50 mg: 10, 20, 30, 40, 50, or 13500 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Furazidin	50 mg

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (1350) – cardboard boxes.
10 pcs. – polymer bottles (1) – cardboard packs.
20 pcs. – polymer bottles (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.
40 pcs. – polymer bottles (1) – cardboard packs.
50 pcs. – polymer bottles (1) – cardboard packs.

Furagin [Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)]
Tablets 50 mg: 10, 20, 30, 50, or 60 pcs.

Marketing Authorization Holder

Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Furagin

Tablets 50 mg: 10, 20, 30, 50, or 60 pcs.

Dosage Form, Packaging, and Composition

Tablets from yellow to yellow-orange in color, round, flat-cylindrical, with a bevel on both sides and a score line on one side.

	1 tab.
Furazidin	50 mg

Excipients : lactose monohydrate – 18.8 mg, sucrose – 10.2 mg, potato starch – 20 mg, calcium stearate – 1 mg.

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.

Furagin [YUGPHARM, LLC (Russia)]
Capsules 50 mg: 10, 20, 30, 40, 50 or 60 pcs.

Marketing Authorization Holder

YUGPHARM, LLC (Russia)

Dosage Form

Furagin

Capsules 50 mg: 10, 20, 30, 40, 50 or 60 pcs.

Dosage Form, Packaging, and Composition

Capsules hard gelatin size No. 2, with an orange body and cap; the capsule contents are an orange powder; the presence of white particles and compaction of the capsule contents into lumps that crumble when pressed is allowed.

	1 tab.
Furazidine sodium tetrahydrate	62.5 mg,
Equivalent to furazidine sodium content	50 mg

Excipients: magnesium hydroxycarbonate – 72 mg, pregelatinized corn starch – 45.2 mg, colloidal silicon dioxide A-200 – 6.3 mg, croscarmellose sodium – 12 mg, talc – 2 mg.

Capsule (body and cap) titanium dioxide – 1.4%, sunset yellow FCF dye – 2.25%, gelatin – up to 100%.

Furagin [YUGPHARM, LLC (Russia)]
Tablets 50 mg: 10, 20, 30, 40, 50, or 60 pcs.

Marketing Authorization Holder

YUGPHARM, LLC (Russia)

Dosage Form

Furagin

Tablets 50 mg: 10, 20, 30, 40, 50, or 60 pcs.

Dosage Form, Packaging, and Composition

Tablets from yellow to yellow with an orange tint, round, flat-cylindrical, with a bevel.

	1 tab.
Furazidin	50 mg

Excipients: lactose monohydrate – 36 mg, corn starch – 7 mg, povidone K-17 – 4 mg, croscarmellose sodium – 2 mg, magnesium stearate – 1 mg.

Furagin Avexima [Avexima JSC (Russia)]
Tablets 50 mg: 10, 20, 30, or 50 pcs.

Marketing Authorization Holder

Avexima JSC (Russia)

Manufactured By

Irbit Chemical Pharmaceutical Plant, JSC (Russia)

Avexima Siberia LLC (Russia)

Dosage Form

Furagin Avexima

Tablets 50 mg: 10, 20, 30, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets yellow-orange in color, round, flat-cylindrical, with a score on one side and a bevel on both sides.

	1 tab.
Furazidin	50 mg

Excipients: corn starch – 27.5 mg, sucrose – 13.75 mg, anhydrous colloidal silicon dioxide – 1.25 mg, stearic acid – 7.5 mg.

Furagin Renewal [Obnovlenie Pfc, JSC (Russia)]
Film-coated tablets 50 mg

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Furagin Renewal

Film-coated tablets 50 mg

Dosage Form, Packaging, and Composition

Film-coated tablets

	1 tab.
Furazidin	50 mg

10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (12 pcs.) – cardboard packs (120 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
15 pcs. – contour cell packs – cardboard packs (15 pcs.) – By prescription
15 pcs. – contour cell packs (2 pcs.) – cardboard packs (30 pcs.) – By prescription
15 pcs. – contour cell packs (4 pcs.) – cardboard packs (60 pcs.) – By prescription
15 pcs. – contour cell packs (6 pcs.) – cardboard packs (90 pcs.) – By prescription
15 pcs. – contour cell packs (8 pcs.) – cardboard packs (120 pcs.) – By prescription

Furagin-Aktifur [Aliym, JSC (Russia)]
Capsules 25 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, 80, 90, 100, 120 or 150 pcs.
Capsules 50 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, 80, 90, 100, 120 or 150 pcs.

Marketing Authorization Holder

Aliym, JSC (Russia)

Dosage Forms

	Furagin-Aktifur	Capsules 25 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, 80, 90, 100, 120 or 150 pcs.
		Capsules 50 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, 80, 90, 100, 120 or 150 pcs.

Dosage Form, Packaging, and Composition

Capsules hard gelatin size No. 3 with a yellow body and cap; the capsule contents are an orange powder.

	1 caps.
Furazidin sodium	31.25 mg,
Equivalent to furazidin content	25 mg

Excipients: magnesium carbonate basic hydrated – 36 mg, pregelatinized corn starch – 22.6 mg, colloidal silicon dioxide (aerosil) – 3.15 mg, croscarmellose sodium – 6 mg, talc – 1 mg.

Composition of hard gelatin capsules capsule body and cap – titanium dioxide – 1.3333%, quinoline yellow dye – 0.9197%, sunset yellow FCF dye – 0.0044%, gelatin up to – 100%.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
15 pcs. – contour cell packs (1) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (4) – cardboard packs.
15 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.

Capsules hard gelatin size No. 1 with a yellow body and cap; the capsule contents are an orange powder.

	1 caps.
Furazidin sodium	62.5 mg,
Equivalent to furazidin content	50 mg

Excipients: magnesium carbonate basic hydrated – 72 mg, pregelatinized corn starch – 45.2 mg, colloidal silicon dioxide (aerosil) – 6.3 mg, croscarmellose sodium – 12 mg, talc – 2 mg.

Composition of hard gelatin capsules capsule body and cap – titanium dioxide – 1.3333%, quinoline yellow dye – 0.9197%, sunset yellow FCF dye – 0.0044%, gelatin – up to 100%.

Furagin-Alium [Aliym, JSC (Russia)]
Tablets 50 mg: 10, 15, 20, 30, 45, 60, or 90 pcs.

Marketing Authorization Holder

Aliym, JSC (Russia)

Dosage Form

Furagin-Alium

Tablets 50 mg: 10, 15, 20, 30, 45, 60, or 90 pcs.

Dosage Form, Packaging, and Composition

Tablets from yellow to yellow with an orange tint, round, flat-cylindrical, with a bevel.

	1 tab.
Furazidin	50 mg

Excipients: lactose monohydrate, microcrystalline cellulose, potato starch, crospovidone (kollidon CL-M), crospovidone (polyplasdone XL-10), povidone K17 (low molecular weight polyvinylpyrrolidone), croscarmellose sodium, polysorbate 80 (tween 80), calcium stearate.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (1) – cardboard packs.
15 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.

Furagin-LekT [Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)]
Tablets 50 mg: 30 pcs.

Marketing Authorization Holder

Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Furagin-LekT

Tablets 50 mg: 30 pcs.

Dosage Form, Packaging, and Composition

Tablets from yellow to yellow with an orange tint, round, flat-cylindrical in shape, with a bevel.

	1 tab.
Furazidin	50 mg

Excipients: potato starch – 20 mg, lactose monohydrate (milk sugar) – 18.8 mg, sucrose (sugar) – 10 mg, calcium stearate – 1 mg, polysorbate-80 (tween-80) – 0.2 mg.

10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour non-cell packs (3) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.

Furagin-SZ [Severnaya Zvezda NAO (Russia)]
Tablets 50 mg: 10, 30, 50, 60, 90, 100, or 120 pcs.

Marketing Authorization Holder

Severnaya Zvezda NAO (Russia)

Dosage Form

Furagin-SZ

Tablets 50 mg: 10, 30, 50, 60, 90, 100, or 120 pcs.

Dosage Form, Packaging, and Composition

Tablets from greenish-yellow to yellow with an orange tint, flat-cylindrical in shape with a bevel.

	1 tab.
Furazidin	50 mg

Excipients: lactose monohydrate (milk sugar) – 18.8 mg, sucrose (sugar) – 18 mg, potato starch – 11.2 mg, stearic acid – 1 mg, polysorbate (tween-80) – 1 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.
50 pcs. – polymer bottles (1) – cardboard packs.

Medixlife (Author)

View all posts Profile link